Name: | pemetrexed |
---|---|
PubChem Compound ID: | 125891 |
Molecular formula: | C20H19N5Na2O6 |
Molecular weight: | 471.375 g/mol |
Synonyms: |
Rolazar; Alimta; LY 231514; 150399-23-8; Tifolar; Pemetrexed disodium; LY 231514 disodium; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
|
Name: | pemetrexed |
---|---|
Name (isomeric): | DB00642 |
Drug Type: | small molecule |
Synonyms: |
Pemetrexed Disodium; LY231514
|
Brand: | Alimta |
Category: | Antimetabolites, Antimetabolites, Antineoplastic, Antineoplastic Agents, Enzyme Inhibitors, Folic Acid Antagonists |
CAS number: | 150399-23-8 |
Indication: | Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy |
---|---|
Pharmacology: | Preclinical studies have shown that pemetrexed inhibits the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052). Studies with the MSTO-211H mesothelioma cell line showed synergistic effects when pemetrexed was combined concurrently with cisplatin. |
Mechanism of Action: |
Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltra...
show more » |
Protein binding: | 81% |
Biotransformation: | Metabolized by Cytochrome P450 Enzymes |
Route of elimination: | Pemetrexed is not metabolized to an appreciable extent and is primarily eliminated in the urine, with 70% to 90% of the dose recovered unchanged within the first 24 hours following administration. |
Half Life: | 3.5 hours |
Clearance: | 91.8 mL/min [Cancer patients with normal renal function receiving 0.2 to 838 mg/m2 infusion over a 10-minute period] |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|